The FDA and U.S. Federal Trade Commission (FTC) announced today that they signed a joint statement to encourage collaboration in support of a robust marketplace for biological products, including the critical adoption of biosimilars and interchangeable products.
The two agencies said the statement sets out to address false or misleading promotion about biosimilars within the respective authorities and to deter anticompetitive behavior in the space as well.
Get the full story at our sister site, Drug Discovery & Development